Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Employees - 46, CEO - Mr. Christian Kanstrup M.Sc., Sector - Healthcare, Country - DK, Market Cap -

Altman ZScore(max is 10): -15.3, Piotroski Score(max is 10): 4, Working Capital: $4397000, Total Assets: $12485000, Retained Earnings: $-118538680, EBIT: -10801716, Total Liabilities: $14137000, Revenue: $3353283

- Current Price $ - Analyst Target Price $